{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:53:43Z","timestamp":1787849623986,"version":"build-2784847793"},"reference-count":138,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.nbd.2019.104707","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T17:29:53Z","timestamp":1575998993000},"page":"104707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"special_numbering":"C","title":["Advances and considerations in AD tau-targeted immunotherapy"],"prefix":"10.1016","volume":"134","author":[{"given":"Alice","family":"Bittar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nemil","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakez","family":"Kayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2019.104707_bb0005","doi-asserted-by":"crossref","first-page":"P592","DOI":"10.1016\/j.jalz.2017.07.227","article-title":"Preclinical characterization of an antibody [LY3303560] targeting aggregated tau","volume":"13","author":"Alam","year":"2017","journal-title":"Alzheim. Dement."},{"key":"10.1016\/j.nbd.2019.104707_bb0010","doi-asserted-by":"crossref","DOI":"10.1186\/s13578-016-0124-4","article-title":"Function and regulation of tau conformations in the development and treatment of traumatic brain injury and neurodegeneration","volume":"6","author":"Albayram","year":"2016","journal-title":"Cell Biosci."},{"key":"10.1016\/j.nbd.2019.104707_bb0015","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-01068-4","article-title":"Cis P-tau is induced in clinical and preclinical brain injury and contributes to post-injury sequelae","volume":"8","author":"Albayram","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.nbd.2019.104707_bb0020","first-page":"443","article-title":"Targeting prion-like Cis phosphorylated tau pathology in neurodegenerative diseases","volume":"8","author":"Albayram","year":"2018","journal-title":"J. Alzheim. Dis. Park."},{"key":"10.1016\/j.nbd.2019.104707_bb0025","doi-asserted-by":"crossref","first-page":"9115","DOI":"10.1523\/JNEUROSCI.2361-07.2007","article-title":"Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements","volume":"27","author":"Asuni","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104707_bb0030","doi-asserted-by":"crossref","DOI":"10.15171\/bi.2016.30","article-title":"Blood-brain barrier transport machineries and targeted therapy of brain diseases","author":"Barar","year":"2016","journal-title":"BioImpacts."},{"key":"10.1016\/j.nbd.2019.104707_bb0035","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nbd.2019.104707_bb0040","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-018-0046-8","article-title":"Prospects for strain-specific immunotherapy in Alzheimer\u2019s disease and tauopathies","volume":"3","author":"Bittar","year":"2018","journal-title":"npj Vaccines"},{"key":"10.1016\/j.nbd.2019.104707_bb0045","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","article-title":"Amyloid-\u03b2 and tau: the trigger and bullet in Alzheimer disease pathogenesisamyloid-\u03b2 and TauAmyloid-\u03b2 and tau","volume":"71","author":"Bloom","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.nbd.2019.104707_bb0050","doi-asserted-by":"crossref","first-page":"16559","DOI":"10.1523\/JNEUROSCI.4363-10.2010","article-title":"Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model","volume":"30","author":"Boutajangout","year":"2010","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.nbd.2019.104707_bb1000","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1474-4422(19)30139-5","article-title":"Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial","volume":"18","author":"Boxer","year":"2019","journal-title":"Lancet. Neurol."},{"key":"10.1016\/j.nbd.2019.104707_bb0055","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2362","article-title":"Tau and A\u03b2 imaging, CSF measures, and cognition in Alzheimer\u2019s disease","volume":"8","author":"Brier","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.nbd.2019.104707_bb0060","doi-asserted-by":"crossref","DOI":"10.1001\/archgenpsychiatry.2011.155","article-title":"Cerebrospinal fluid levels of beta-amyloid 1\u201342, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia","author":"Buchhave","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.nbd.2019.104707_bb0065","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1021\/cn500148z","article-title":"The role of tau oligomers in the onset of Alzheimer\u2019s disease neuropathology","volume":"5","author":"C\u00e1rdenas-Aguayo","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.nbd.2019.104707_bb0070","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1474-4422(18)30232-1","article-title":"The role of TREM2 in Alzheimer\u2019s disease and other neurodegenerative disorders","volume":"17","author":"Carmona","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2019.104707_bb0075","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.4989-14.2015","article-title":"Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer\u2019s disease mouse model","volume":"35","author":"Castillo-Carranza","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104707_bb0080","doi-asserted-by":"crossref","first-page":"34457","DOI":"10.1074\/jbc.M111.229633","article-title":"Passive immunization with anti-tau antibodies in two transgenic models: reduction of tau pathology and delay of disease progression","volume":"286","author":"Chai","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2019.104707_bb0085","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.brainres.2017.10.016","article-title":"Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer\u2019s disease patients: A CSF and FDG PET study","volume":"1678","author":"Chiaravalloti","year":"2018","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2019.104707_bb0090","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-24276-4","article-title":"Tau antibody structure reveals a molecular switch defining a pathological conformation of the tau protein","volume":"8","author":"Chukwu","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.nbd.2019.104707_bb0095","doi-asserted-by":"crossref","first-page":"35452","DOI":"10.1074\/jbc.M113.491001","article-title":"Antibody uptake into neurons occurs primarily via clathrin-dependent Fc\u03b3 receptor endocytosis and is a prerequisite for acute tau protein clearance","volume":"288","author":"Congdon","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2019.104707_bb0100","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.trci.2018.03.009","article-title":"Alzheimer\u2019s disease drug development pipeline: 2018","volume":"4","author":"Cummings","year":"2018","journal-title":"Alzheim. Dement. (New York, N. Y.)"},{"key":"10.1016\/j.nbd.2019.104707_bb0105","doi-asserted-by":"crossref","DOI":"10.14283\/jpad.2019.14","article-title":"Anti-tau trials for Alzheimer\u2019s disease: a report from the EU\/US\/CTAD task force","author":"Cummings","year":"2019","journal-title":"J. Prev. Alzheim. Dis."},{"key":"10.1016\/j.nbd.2019.104707_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062402","article-title":"Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity","volume":"8","author":"d\u2019Abramo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2019.104707_bb0115","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00702-014-1315-y","article-title":"Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies","volume":"122","author":"Dai","year":"2015","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.nbd.2019.104707_bb0120","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.90.15_supplement.P6.073","article-title":"Efficacy and safety of BIIB092 in patients with progressive supranuclear palsy: PASSPORT Phase 2 Study Design (P6.073)","volume":"90","author":"Dam","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2019.104707_bb0125","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jamaneurol.2014.4068","article-title":"Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease","volume":"72","author":"Dorey","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.nbd.2019.104707_bb0130","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-018-0637-7","article-title":"Different tau species lead to heterogeneous tau pathology propagation and misfolding","volume":"6","author":"Dujardin","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.nbd.2019.104707_bb0135","doi-asserted-by":"crossref","first-page":"14421","DOI":"10.1021\/acs.jpcb.5b08092","article-title":"Tau aggregation propensity engrained in its solution state","volume":"119","author":"Eschmann","year":"2015","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.nbd.2019.104707_bb0140","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1016\/j.celrep.2018.03.021","article-title":"Extracellular monomeric and aggregated tau efficiently enter human neurons through overlapping but distinct pathways","volume":"22","author":"Evans","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.nbd.2019.104707_bb0145","doi-asserted-by":"crossref","DOI":"10.1038\/srep19393","article-title":"Extracellular tau oligomers produce an immediate impairment of LTP and memory","volume":"6","author":"F\u00e1","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.nbd.2019.104707_bb0150","first-page":"343","article-title":"Cerebrospinal fluid tau\/\u03b2-Amyloid42 ratio as a prediction of cognitive decline in nondemented older adults","volume":"64","author":"Fagan","year":"2007","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.nbd.2019.104707_bb0155","doi-asserted-by":"crossref","DOI":"10.1212\/01.WNL.0000063313.57292.00","article-title":"Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury","volume":"60","author":"Franz","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2019.104707_bb0160","doi-asserted-by":"crossref","first-page":"12845","DOI":"10.1074\/jbc.M808759200","article-title":"Propagation of tau misfolding from the outside to the inside of a cell","volume":"284","author":"Frost","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2019.104707_bb0165","doi-asserted-by":"crossref","first-page":"21652","DOI":"10.1074\/jbc.M115.657924","article-title":"Distinct therapeutic mechanisms of tau antibodies: promoting microglial clearance versus blocking neuronal uptake","volume":"290","author":"Funk","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2019.104707_bb0170","doi-asserted-by":"crossref","DOI":"10.1038\/s41582-019-0242-9","article-title":"Inflammatory pathways relate to early Alzheimer disease pathology","author":"Fyfe","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.nbd.2019.104707_bb0175","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1089\/neu.2015.4262","article-title":"Tau oligomers derived from traumatic brain injury cause cognitive impairment and accelerate onset of pathology in Htau mice","volume":"33","author":"Gerson","year":"2016","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.nbd.2019.104707_bb0180","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nrneurol.2013.223","article-title":"Alzheimer disease therapy\u2014moving from amyloid-\u03b2 to tau","volume":"9","author":"Giacobini","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.nbd.2019.104707_bb0185","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.1016\/j.febslet.2006.07.078","article-title":"Extracellular tau is toxic to neuronal cells","volume":"580","author":"G\u00f3mez-Ramos","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.nbd.2019.104707_bb0190","doi-asserted-by":"crossref","DOI":"10.1126\/science.1062097","article-title":"Formation of neurofibrillary tangles in P301L tau transgenic mice induced by A\u03b242 fibrils","volume":"293","author":"G\u00f6tz","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.nbd.2019.104707_bb0195","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-018-0298-9","article-title":"New insights into the role of TREM2 in Alzheimer\u2019s disease","volume":"13","author":"Gratuze","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.nbd.2019.104707_bb0200","doi-asserted-by":"crossref","first-page":"33081","DOI":"10.1074\/jbc.M113.494922","article-title":"Two novel tau antibodies targeting the 396\/404 region are primarily taken up by neurons and reduce tau protein pathology","volume":"288","author":"Gu","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2019.104707_bb0205","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3389\/fncel.2015.00464","article-title":"Tau oligomers: the toxic player at synapses in Alzheimer\u2019s disease","volume":"9","author":"Guerrero-Mu\u00f1oz","year":"2015","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.nbd.2019.104707_bb0210","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-018-0384-9","article-title":"Immunotherapy to improve cognition and reduce pathological species in an Alzheimer\u2019s disease mouse model","volume":"10","author":"Herline","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nbd.2019.104707_bb0215","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0304-3940(00)01697-9","article-title":"Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke","volume":"297","author":"Hesse","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.nbd.2019.104707_bb0220","doi-asserted-by":"crossref","first-page":"e995","DOI":"10.1038\/tp.2016.252","article-title":"Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration","volume":"7","author":"H\u00f6glund","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.nbd.2019.104707_bb0225","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/13543784.2019.1619694","article-title":"Tau immunotherapies for Alzheimer\u2019s disease","volume":"28","author":"Hoskin","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.nbd.2019.104707_bb0230","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s13361-017-1815-8","article-title":"Probing conformational dynamics of tau protein by hydrogen\/deuterium exchange mass spectrometry","volume":"29","author":"Huang","year":"2018","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.nbd.2019.104707_bb0235","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.2353\/ajpath.2010.100346","article-title":"A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model","volume":"177","author":"Hurtado","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.nbd.2019.104707_bb0240","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-019-0664-z","article-title":"A walk through tau therapeutic strategies","volume":"7","author":"Jadhav","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.nbd.2019.104707_bb0245","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E","article-title":"Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau","volume":"48","author":"Jicha","year":"1997","journal-title":"J. Neurosci. Res."},{"issue":"25","key":"10.1016\/j.nbd.2019.104707_bb0250","article-title":"Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer\u2019s disease","volume":"12","author":"Kametani","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.nbd.2019.104707_bb0255","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/jnen\/nlv001","article-title":"Characterization of early pathological tau conformations and phosphorylation in chronic traumatic encephalopathy","volume":"75","author":"Kanaan","year":"2016","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.nbd.2019.104707_bb0260","doi-asserted-by":"crossref","first-page":"10851","DOI":"10.1523\/JNEUROSCI.0387-15.2015","article-title":"C-terminally truncated forms of tau, but not full-length tau or its C-terminal fragments, are released from neurons independently of cell death","volume":"35","author":"Kanmert","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104707_bb0265","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00401-018-1855-6","article-title":"Tau seeding activity begins in the transentorhinal\/entorhinal regions and anticipates phospho-tau pathology in Alzheimer\u2019s disease and PART","volume":"136","author":"Kaufman","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2019.104707_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2017.07.243","article-title":"A phase I study to evaluate the safety and tolerability of RO7105705 in healthy volunteers and patients with mild-to-moderate AD","volume":"13","author":"Kerchner","year":"2017","journal-title":"Alzheim. Dement."},{"key":"10.1016\/j.nbd.2019.104707_bb0275","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.nbd.2019.104707_bb0280","doi-asserted-by":"crossref","first-page":"P398","DOI":"10.1016\/j.jalz.2016.06.751","article-title":"Occurrence of tau oligomers in serum of cognitively normal individuals","volume":"12","author":"Kolarova","year":"2016","journal-title":"Alzheim. Dement."},{"key":"10.1016\/j.nbd.2019.104707_bb0285","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature14658","article-title":"Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy","volume":"523","author":"Kondo","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2019.104707_bb0290","doi-asserted-by":"crossref","first-page":"16835","DOI":"10.1523\/JNEUROSCI.2755-14.2014","article-title":"Antibody-derived in vivo imaging of tau pathology","volume":"34","author":"Krishnaswamy","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104707_bb0295","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1096\/fj.11-199851","article-title":"Identification of oligomers at early stages of tau aggregation in Alzheimer\u2019s disease","volume":"26","author":"Lasagna-Reeves","year":"2012","journal-title":"FASEB J."},{"key":"10.1016\/j.nbd.2019.104707_bb0300","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.031781","article-title":"Molecular biomarkers of Alzheimer's disease: progress and prospects","volume":"11","author":"Lashley","year":"2018","journal-title":"Dis. Model Mech."},{"key":"10.1016\/j.nbd.2019.104707_bb0305","doi-asserted-by":"crossref","DOI":"10.1038\/s12276-019-0250-2","article-title":"Diagnosis of Alzheimer\u2019s disease utilizing amyloid and tau as fluid biomarkers","volume":"51","author":"Lee","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.nbd.2019.104707_bb0310","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","article-title":"Tau PET imaging in neurodegenerative tauopathies\u2014still a challenge","volume":"24","author":"Leuzy","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.nbd.2019.104707_bb0315","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.trci.2016.06.004","article-title":"NPT088 reduces both amyloid-\u03b2 and tau pathologies in transgenic mice","volume":"2","author":"Levenson","year":"2016","journal-title":"Alzheim. Dement. (New York, N. Y.)"},{"key":"10.1016\/j.nbd.2019.104707_bb0320","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/15622975.2017.1375556","article-title":"Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the consensus of the task force on biological markers in psychiatry of the world federation of societies of biological psychiatry","volume":"19","author":"Lewczuk","year":"2018","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.nbd.2019.104707_bb0325","doi-asserted-by":"crossref","DOI":"10.1126\/science.1058189","article-title":"Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP","volume":"293","author":"Lewis","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.nbd.2019.104707_bb0330","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/14737175.2016.1204234","article-title":"Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer\u2019s disease","volume":"17","author":"Lista","year":"2017","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.nbd.2019.104707_bb0335","doi-asserted-by":"crossref","first-page":"12425","DOI":"10.1523\/JNEUROSCI.2016-16.2016","article-title":"Vectored intracerebral immunization with the anti-tau monoclonal antibody PHF1 markedly reduces tau pathology in mutant tau transgenic mice","volume":"36","author":"Liu","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104707_bb0340","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/brain\/awx320","article-title":"Widespread brain tau and its association with ageing, Braak stage and Alzheimer\u2019s dementia","volume":"141","author":"Lowe","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2019.104707_bb0345","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3233\/JAD-2007-12410","article-title":"Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer\u2019s disease","volume":"12","author":"Luna-Munoz","year":"2007","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.nbd.2019.104707_bb0350","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.neures.2005.11.009","article-title":"Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer\u2019s disease","volume":"54","author":"Maeda","year":"2006","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.nbd.2019.104707_bb0355","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/brain\/awr286","article-title":"Tau elevations in the brain extracellular space correlate with reduced amyloid-\u03b2 levels and predict adverse clinical outcomes after severe traumatic brain injury","volume":"135","author":"Magnoni","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2019.104707_bb0360","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jama.2009.1064","article-title":"CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment","volume":"302","author":"Mattsson","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.nbd.2019.104707_bb0365","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","article-title":"Plasma tau in Alzheimer disease","volume":"87","author":"Mattsson","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2019.104707_bb0370","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1073\/pnas.1607215114","article-title":"Cytosolic fc receptor TRIM21 inhibits seeded tau aggregation","volume":"114","author":"McEwan","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2019.104707_bb0375","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.3390\/ijms19041160","article-title":"An overview on the clinical development of tau-based therapeutics","volume":"19","author":"Medina","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.nbd.2019.104707_bb0380","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3389\/fncel.2014.00113","article-title":"The role of extracellular tau in the spreading of neurofibrillary pathology","volume":"8","author":"Medina","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.nbd.2019.104707_bb0385","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jamaneurol.2017.1359","article-title":"Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo Clinic study on aging","volume":"74","author":"Mielke","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.nbd.2019.104707_bb0390","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.36584","article-title":"Inert and seed-competent tau monomers suggest structural origins of aggregation","volume":"7","author":"Mirbaha","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.nbd.2019.104707_bb0395","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4161\/pri.22849","article-title":"Cis phosphorylated tau as the earliest detectable pathogenic conformation in Alzheimer disease, offering novel diagnostic and therapeutic strategies","volume":"7","author":"Nakamura","year":"2013","journal-title":"Prion"},{"key":"10.1016\/j.nbd.2019.104707_bb0400","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2019.104707_bb0405","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1021\/acschemneuro.8b00629","article-title":"cis pT231-tau drives neurodegeneration in bipolar disorder","volume":"10","author":"Naserkhaki","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.nbd.2019.104707_bb0410","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-018-0557-6","article-title":"Phosphorylation of different tau sites during progression of Alzheimer\u2019s disease","volume":"6","author":"Neddens","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.nbd.2019.104707_bb0415","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/brain\/awx052","article-title":"Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model","volume":"140","author":"Nisbet","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2019.104707_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(16)30331-3","article-title":"Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled, phase 1 trial","author":"Novak","year":"2017","journal-title":"Lancet Neurol."},{"issue":"798","key":"10.1016\/j.nbd.2019.104707_bb0425","article-title":"Ten years of tau-targeted Immunotherapy: the path walked and the roads ahead","volume":"12","author":"Novak","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.nbd.2019.104707_bb0430","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-018-0436-1","article-title":"FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer\u2019s disease","volume":"10","author":"Novak","year":"2018","journal-title":"Alzheimers Res. Ther."},{"issue":"3","key":"10.1016\/j.nbd.2019.104707_bb0435","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.neuron.2004.07.003","article-title":"Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome","volume":"43","author":"Oddo","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2019.104707_bb0440","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-007-9374-5","article-title":"Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development","author":"Ohtsuki","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.nbd.2019.104707_bb0445","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2019.104707_bb0450","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ana.25410","article-title":"Amyloid-\u03b2 immunotherapy for alzheimer disease: is it now a long shot?","volume":"85","author":"Panza","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2019.104707_bb0455","doi-asserted-by":"crossref","DOI":"10.1038\/nrd725","article-title":"Drug and gene targeting to the brain with molecular Trojan horses","author":"Pardridge","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.nbd.2019.104707_bb0460","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/mp.2016.37","article-title":"Amyloid-\u03b2 and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer\u2019s disease","volume":"22","author":"Pascoal","year":"2017","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.nbd.2019.104707_bb0465","first-page":"781","article-title":"18F-AV-1451 positron emission tomography in Alzheimer\u2019s disease and progressive supranuclear palsy","volume":"140","author":"Passamonti","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2019.104707_bb2000","series-title":"Antibodies specific for hyperphosphorylated tau and methods of use thereof","author":"Pedersen","year":"2017"},{"key":"10.1016\/j.nbd.2019.104707_bb0470","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrneurol.2017.162","article-title":"Amyloid-\u03b2 and tau complexity \u2014 towards improved biomarkers and targeted therapies","volume":"14","author":"Polanco","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.nbd.2019.104707_bb0475","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.trci.2018.10.007","article-title":"A randomized, single ascending dose study of intravenous BIIB092 in healthy participants","volume":"4","author":"Qureshi","year":"2018","journal-title":"Alzheim. Dement. (New York, N. Y.)"},{"key":"10.1016\/j.nbd.2019.104707_bb0480","doi-asserted-by":"crossref","first-page":"P1077","DOI":"10.1016\/j.jalz.2018.06.1388","article-title":"Randomized, double-blind, placebo-controlled study to assess treatment of biib092 in subjects with early alzheimer\u2019s disease: tango phase 2 study design","volume":"14","author":"Ratti","year":"2018","journal-title":"Alzheim. Dement."},{"key":"10.1016\/j.nbd.2019.104707_bb0485","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1093\/hmg\/dds297","article-title":"Enhanced \u03b2-secretase processing alters APP axonal transport and leads to axonal defects","volume":"21","author":"Rodrigues","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2019.104707_bb0490","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1460-9568.2007.05341.x","article-title":"Axonal accumulation of synaptic markers in APP transgenic Drosophila depends on the NPTY motif and is paralleled by defects in synaptic plasticity","volume":"25","author":"Rusu","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104707_bb0495","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-019-1299-4","article-title":"ApoE4: an emerging therapeutic target for Alzheimer\u2019s disease","volume":"17","author":"Safieh","year":"2019","journal-title":"BMC Med."},{"key":"10.1016\/j.nbd.2019.104707_bb0500","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.2174\/13816128113199990463","article-title":"Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?","volume":"20","author":"Sanchez-Covarrubias","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.nbd.2019.104707_bb0505","doi-asserted-by":"crossref","first-page":"e0125614","DOI":"10.1371\/journal.pone.0125614","article-title":"Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models","volume":"10","author":"Sankaranarayanan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2019.104707_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2018.02.015","article-title":"Tau kinetics in neurons and the human central nervous system","volume":"97","author":"Sato","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2019.104707_bb0515","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.mcn.2018.12.001","article-title":"Biomarkers for tau pathology","volume":"97","author":"Sch\u00f6ll","year":"2019","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.nbd.2019.104707_bb0520","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2217\/17520363.2.4.363","article-title":"Tau as a biomarker of neurodegenerative diseases","volume":"2","author":"Schraen-Maschke","year":"2008","journal-title":"Biomark. Med"},{"key":"10.1016\/j.nbd.2019.104707_bb0525","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11481-015-9637-6","article-title":"Tau-directed immunotherapy: a promising strategy for treating Alzheimer\u2019s disease and other tauopathies","volume":"11","author":"Schroeder","year":"2016","journal-title":"J. NeuroImmune Pharmacol."},{"key":"10.1016\/j.nbd.2019.104707_bb0530","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/ijms19040998","article-title":"The neurotoxic role of extracellular tau protein","volume":"19","author":"Sebasti\u00e1n-Serrano","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.nbd.2019.104707_bb0535","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/acn3.382","article-title":"Tau oligomers in cerebrospinal fluid in Alzheimer\u2019s disease","volume":"4","author":"Sengupta","year":"2017","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.nbd.2019.104707_bb0540","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2217\/fnl-2018-0003","article-title":"Role of FABP3 as biomarker in Alzheimer\u2019s disease and synucleinopathies","volume":"13","author":"Sepe","year":"2018","journal-title":"Future Neurol."},{"key":"10.1016\/j.nbd.2019.104707_bb0545","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fnagi.2017.00083","article-title":"Tau oligomers: cytotoxicity, propagation, and mitochondrial damage","volume":"9","author":"Shafiei","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.nbd.2019.104707_bb0550","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/21645515.2017.1393594","article-title":"Tau immunotherapy: hopes and hindrances","volume":"14","author":"Shahpasand","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.nbd.2019.104707_bb0555","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature24016","article-title":"ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy","volume":"549","author":"Shi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2019.104707_bb0560","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nri2508","article-title":"B-cell responses to vaccination at the extremes of age","volume":"9","author":"Siegrist","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.nbd.2019.104707_bb0565","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000440842","article-title":"Tau immunotherapy","volume":"16","author":"Sigurdsson","year":"2016","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.nbd.2019.104707_bb0570","doi-asserted-by":"crossref","first-page":"S555","DOI":"10.3233\/JAD-179937","article-title":"Tau immunotherapies for Alzheimer\u2019s disease and related tauopathies: progress and potential pitfalls","volume":"64","author":"Sigurdsson","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.nbd.2019.104707_bb0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-018-0301-5","article-title":"Early increase of CSF sTREM2 in Alzheimer\u2019s disease is associated with tau related-neurodegeneration but not with amyloid-\u03b2 pathology","volume":"14","author":"Su\u00e1rez-Calvet","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.nbd.2019.104707_bb0580","article-title":"Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimer\u2019s disease","volume":"2","author":"Tai","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.nbd.2019.104707_bb0585","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00401-015-1415-2","article-title":"Extracellular association of APP and tau fibrils induces intracellular aggregate formation of tau","volume":"129","author":"Takahashi","year":"2015","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2019.104707_bb0590","doi-asserted-by":"crossref","first-page":"e72301","DOI":"10.1371\/journal.pone.0072301","article-title":"Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in Tau.P301L mice that model tauopathy","volume":"8","author":"Theunis","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2019.104707_bb0595","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3233\/JAD-160695","article-title":"Novel phospho-tau monoclonal antibody generated using a liposomal vaccine, with enhanced recognition of a conformational tauopathy epitope","volume":"56","author":"Theunis","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.nbd.2019.104707_bb0600","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2174\/156720512800492503","article-title":"Targeting phospho-Ser422 by active tau immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach","volume":"9","author":"Troquier","year":"2012","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.nbd.2019.104707_bb0605","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/acn3.171","article-title":"Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice","volume":"2","author":"Umeda","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.nbd.2019.104707_bb0610","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-018-0585-2","article-title":"Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice","volume":"6","author":"Vitale","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.nbd.2019.104707_bb0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2017.12.019","article-title":"Brain shuttle antibody for Alzheimer\u2019s disease with attenuated peripheral effector function due to an inverted binding mode","author":"Weber","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.nbd.2019.104707_bb0620","article-title":"Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer\u2019s disease and other tauopathies","author":"West","year":"2017","journal-title":"J. Prev. Alzheim. Dis."},{"key":"10.1016\/j.nbd.2019.104707_bb0625","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000004667","article-title":"Serum neurofilament light in familial Alzheimer disease","volume":"89","author":"Weston","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2019.104707_bb0630","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1074\/jbc.M112.394528","article-title":"Small misfolded tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons","volume":"288","author":"Wu","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2019.104707_bb0635","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.4103\/0366-6999.220313","article-title":"Tau-mediated neurodegeneration and potential implications in diagnosis and treatment of Alzheimer\u2019s disease","volume":"130","author":"Wu","year":"2017","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.nbd.2019.104707_bb0640","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ebiom.2018.08.041","article-title":"Dynamic assessment of tau immunotherapies in the brains of live animals by two-photon imaging","volume":"35","author":"Wu","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.nbd.2019.104707_bb0645","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3389\/fnins.2017.00667","article-title":"Extracellular tau and its potential role in the propagation of tau pathology","volume":"11","author":"Yamada","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.nbd.2019.104707_bb0650","doi-asserted-by":"crossref","first-page":"10841","DOI":"10.1074\/jbc.H118.003970","article-title":"The sulfation code for propagation of neurodegeneration","volume":"293","author":"Yamada","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2019.104707_bb0655","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.neuron.2013.07.046","article-title":"Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo","volume":"80","author":"Yanamandra","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2019.104707_bb0660","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/acn3.176","article-title":"Anti-tau antibody reduces insoluble tau and decreases brain atrophy","volume":"2","author":"Yanamandra","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.nbd.2019.104707_bb0665","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009835","article-title":"Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates","volume":"6","author":"Yu","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.nbd.2019.104707_bb0670","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1139\/bcb-2016-0227","article-title":"Structural evaluations of tau protein conformation: methodologies and approaches","volume":"95","author":"Zabik","year":"2017","journal-title":"Biochem. Cell Biol."},{"key":"10.1016\/j.nbd.2019.104707_bb0675","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/nan.12378","article-title":"Review: tau in biofluids \u2013 relation to pathology, imaging and clinical features","volume":"43","author":"Zetterberg","year":"2017","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.nbd.2019.104707_bb0680","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jneumeth.2018.10.025","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease\u2014An update","volume":"319","author":"Zetterberg","year":"2019","journal-title":"J. Neurosci. Methods"}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996119303821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996119303821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:25:49Z","timestamp":1760851549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996119303821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":138,"alternative-id":["S0969996119303821"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2019.104707","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances and considerations in AD tau-targeted immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2019.104707","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104707"}}